NeuroJournal

Six Biologics, One Disease, Zero Head-to-Head Trials: How Do You Actually Choose in Myasthenia Gravis?

Six FDA-approved biologics now compete for the same generalized myasthenia gravis patient — three complement inhibitors, three FcRn antagonists, and not a single head-to-head trial to guide us. The "refractory…

Sara Lindgren

May 13, 2026